You're viewing a public gap. Sign up free to track live gaps, get alerts, and see the full analysis.

🏥health TRENDING● watch
65

High Gap

Eli Lilly's EloraTZP shows 23.3% weight loss in Phase 2 trial

"Eli Lilly Closely" is generating significant organic discussion across health communities, with 11 posts and 0 comments tracked. Key terms: eli lilly closely, lilly closely watched, closely watched combo, watched combo obesity, combo obesity regimen.

First seen 3h ago
Updated 3h ago
North America
R
Peaking

Signal sources

1article in major outlets

What people are saying

# SHORT SYNTHESIS

Eli Lilly announced Phase 2 trial results for EloraTZP, a combination obesity treatment, showing 23.3% weight loss in patients with both obesity and type 2 diabetes. According to posts on Reddit, this result exceeded Zepbound's 14.8% weight loss in a head-to-head comparison, with the stock moving up 0.45% on the news.

Discussion of the announcement is minimal across platforms. Reddit posts are largely duplicates of the same NBC News article across different subreddits, with no visible comment threads or substantive user engagement. The framing in these posts is straightforward and factual—presenting the trial results and comparative weight loss figures without interpretation or debate. No notable disagreement or alternative framings are evident in the available data. The low engagement and absence of discussion threads suggest the announcement has not yet generated significant social media conversation or controversy.

Premium includes thematic clustering, platform disagreement analysis, and claim vs. speculation breakdown.

Read deeper →

See the full conversation

11

Social mentions

10%

Mainstream coverage

+0.60

Sentiment delta· Mostly positive

R

Where this story began · r/NBCauto

[Health] - Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Coverage Timeline

Last 24 hours

Unlock full analysis

Premium includes everything you need to go deep on this story.

  • Coverage timeline chart — social velocity vs. mainstream media over 24h
  • Sentiment delta — how social and mainstream media feel about this story
  • Partner action links — prediction markets, brokers, sportsbooks
  • AI gap analysis — plain-English explanation of why this gap exists
  • Trajectory analysis — observed direction and confidence
Upgrade to Premium

Starting at $9/mo · Cancel anytime

Sources1 mainstream media · 10 social

Platforms Tracking This

reddittwitterbluesky

Sample sources

cnbc.com
Score Breakdown
Social velocity53
Mainstream silence90
Sentiment gap60

Shareable Gap Card

🏥

GapWatch

Health

65
HIGH GAP

Eli Lilly's EloraTZP shows 23.3% weight loss in Phase 2 trial

↑

11

Social

◎

10%

Mainstream media

▲

+0.60 · Mostly positive

Sentiment Δ

Gap Score65/100
#eli lilly closely#lilly closely watched#closely watched combo#watched combo obesity

gapwatch.io

AI Visibility and Brand Intelligence Measurement

TRENDING

Observation, not investment advice. Past gap-score patterns do not guarantee future outcomes.

Tags

#eli lilly closely#lilly closely watched#closely watched combo#watched combo obesity#combo obesity regimen#obesity regimen boosts
Gap Score 65: Eli Lilly Closely | GapWatch